Table 2 Clinicopathological features according to CALN1 methylation percentage
From: CALN1 hypomethylation as a biomarker for high-risk bladder cancer
Variable | All n = 82 | CALN1 methylation | P | ||
|---|---|---|---|---|---|
Low n = 51 | High n = 31 | ||||
CALN1 methylation percentage (IQRa) | 79.5 (51.1, 92.6) | 63.1 (40.7, 78.1) | 97.8 (90.6, 100) | < 0.0001 | |
Follow-up period, month (range) | 11.5 (0–29) | 12 (0–29) | 11 (0–29) | 0.21 | |
Age (range) | 76 (52–93) | 79 (53–93) | 73 (52–85) | < 0.0001 | |
Sex | Female, n (%) | 19 (23) | 17 (33) | 2 (6) | 0.0062 |
Hematuria | Yes, n (%) | 39 (48) | 24 (47) | 15 (48) | 0.91 |
Smoking history | Yes, n (%) | 45 (55) | 23 (45) | 22 (71) | 0.039 |
Brinkman index | (IQR) | 200 (0–700) | 0 (0–490) | 640 (0–990) | 0.0073 |
BCGb therapy | Yes, n (%) | 11 (13) | 7 (13) | 4 (13) | 1 |
Total cystectomy | 9 (11) | 5 (10) | 4 (13) | 0.72 | |
Tumor stage, n (%) | 0.0007 | ||||
Ta | 54 (66) | 27 (53) | 27 (87) | ||
T1 | 19 (23) | 18 (35) | 1 (3) | ||
T2+ | 9 (11) | 6 (12) | 3 (10) | ||
Tumor grade, n (%) | 0.018 | ||||
Low | 62 (76) | 34 (67) | 28 (90) | ||
High | 20 (24) | 17 (33) | 3 (10) | ||
Tumor number, n (%) | 0.65 | ||||
Single | 41 (50) | 24 (47) | 17 (55) | ||
Multiple | 41 (50) | 27 (53) | 14 (45) | ||
Tumor size, n (%) | 0.12 | ||||
< 30 mm | 70 (85) | 41 (80) | 29 (94) | ||
≥ 30 mm | 12 (15) | 10 (20) | 2 (6) | ||
Sample type, n (%) | 0.65 | ||||
Primary | 50 (61) | 30 (59) | 20 (65) | ||
Recurrent | 32 (39) | 21 (41) | 11 (35) | ||